Use of human small leucine zipper protein in adipocyte differentiation procedure
The present invention relates to a use of a human small leucine zipper protein in the adipocyte differentiation procedure. More specifically, sLZIP binds with PPARγ2 to induce the formation of a complex of HDAC3 and PPARγ2, thereby functioning as a corepressor to negatively inhibit the transcriptional activity of PPARγ2 and suppress the differentiation to adipocytes, and thus can be used as a marker for treating diabetes and obesity and developing new medicines therefor.
1. A screening method of a medicine for preventing or treating diabetes, comprising:
contacting a cell transformed with human small leucine-zipper proteins (sLZIP) and Peroxisome proliferator-activated receptor γ2 (PPARγ2) with a candidate material, wherein either the human sLZIP or PPARγ2 is coupled to a detectable component; and
detecting an increase in formation of the complex of the human sLZIP and PPARγ2 in the cell, whereby said candidate material is determined to be a material capable of preventing or treating diabetes.
2. The screening method of claim 1 , wherein the cell is an animal cell.
3. The screening method of claim 2 , wherein the detectable component is selected from the group consisting of a fluorescent protein, Glutathione S transferase (GST), Flag-tag, Myc-tag and HA-tag.
4. The screening method of claim 1 or 2 , wherein detecting is carried out by a reaction using the detectable component, or the human sLZIP or PPARγ2-specific antibody.